Scott A Laurie - JoVE Visualize

Showing results (41-50 of 70) with videos related to

Pageof 7

Sort By:

Clinical Lung Cancer|February 14, 2016

Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non-Small Cell Lung CancerAnthony Brade, Robert MacRae, Scott A Laurie, et al.

Clinical and Translational Science|December 19, 2020

Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung CancerJonathan W Goldman, Minal Barve, Jyoti D Patel, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 19, 2011

Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials GroupScott A Laurie, Ashish Gupta, Quincy Chu, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 27, 2018

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLCScott Gettinger, Matthew D Hellmann, Laura Q M Chow, et al.

European Journal of Cancer (Oxford, England : 1990)|March 16, 2013

Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumoursJean-Charles Soria, José Baselga, Nasser Hanna, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung CancerScott Gettinger, Naiyer A Rizvi, Laura Q Chow, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 22, 2017

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC)Byoung Chul Cho, Dong-Wan Kim, Alessandra Bearz, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung CancerNaiyer A Rizvi, Matthew D Hellmann, Julie R Brahmer, et al.

JCO Precision Oncology|April 18, 2024

Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working GroupErica C Nakajima, Amber Simpson, Jan Bogaerts, et al.

Cancer Epidemiology|January 28, 2016

ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patientsSinead Cuffe, Abul Kalam Azad, Xiaoping Qiu, et al.

Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:

Pageof 7

Clinical Lung Cancer|February 14, 2016

Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non-Small Cell Lung CancerAnthony Brade, Robert MacRae, Scott A Laurie, et al.

Clinical and Translational Science|December 19, 2020

Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung CancerJonathan W Goldman, Minal Barve, Jyoti D Patel, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 19, 2011

Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials GroupScott A Laurie, Ashish Gupta, Quincy Chu, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 27, 2018

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLCScott Gettinger, Matthew D Hellmann, Laura Q M Chow, et al.

European Journal of Cancer (Oxford, England : 1990)|March 16, 2013

Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumoursJean-Charles Soria, José Baselga, Nasser Hanna, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung CancerScott Gettinger, Naiyer A Rizvi, Laura Q Chow, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 22, 2017

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC)Byoung Chul Cho, Dong-Wan Kim, Alessandra Bearz, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung CancerNaiyer A Rizvi, Matthew D Hellmann, Julie R Brahmer, et al.

JCO Precision Oncology|April 18, 2024

Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working GroupErica C Nakajima, Amber Simpson, Jan Bogaerts, et al.

Cancer Epidemiology|January 28, 2016

ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patientsSinead Cuffe, Abul Kalam Azad, Xiaoping Qiu, et al.

Pageof 7